Berthel Fisher & Co Financial Services’s Franklin Genomic Advancements ETF HELX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.9K Hold
401
– – ﹤0.01% 875
2026
Q2
$16K Sell
401
-100
-20% -$3.47K ﹤0.01% 1354
2026
Q1
$16.6K Buy
501
+1
+0.2% +$35 ﹤0.01% 1376
2025
Q4
$18.2K Hold
500
– – ﹤0.01% 1365
2025
Q3
$15.5K Hold
500
– – ﹤0.01% 1358
2025
Q2
$13.9K Hold
500
– – ﹤0.01% 1371
2025
Q1
$13.5K Hold
500
– – ﹤0.01% 1399
2024
Q4
$14.4K Sell
500
-400
-44% -$12.3K ﹤0.01% 1304
2024
Q3
$29.2K Buy
+900
New +$29.4K ﹤0.01% 1134

Other funds holding HELX

Berthel Fisher & Co Financial Services's HELX Position: Q3 2026 in Review

Berthel Fisher & Co Financial Services held its Franklin Genomic Advancements ETF (HELX) position steady in Q3 2026 at 401 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #875.

Berthel Fisher & Co Financial Services first reported a position in HELX in Q3 2024 and has held it in 9 quarters since. The position peaked at $29.2K in Q3 2024. 11 funds tracked by Wall St. Rank hold HELX as of Q3 2026.

  • Berthel Fisher & Co Financial Services held 401 shares of Franklin Genomic Advancements ETF worth $17.9K as of Q3 2026.
  • Berthel Fisher & Co Financial Services left its Franklin Genomic Advancements ETF share count unchanged in Q3 2026.
  • Franklin Genomic Advancements ETF made up ﹤0.01% of Berthel Fisher & Co Financial Services's portfolio in Q3 2026, its #875 holding.
  • Berthel Fisher & Co Financial Services first reported a position in Franklin Genomic Advancements ETF in Q3 2024 and has held it in 9 quarters since.
  • Berthel Fisher & Co Financial Services's Franklin Genomic Advancements ETF position peaked at $29.2K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q3 2026.

Based on Berthel Fisher & Co Financial Services's 13F filing for Q3 2026, filed 13 Nov 2026.